Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis

H Yoshiji, S Kuriyama, J Yoshii, Y Ikenaka, R Naguchi, D J Hicklin, Y Wu, K Yanase, T Namisaki, M Yamazaki, H Tsujinoue, H Imazu, T Masaki, H Fukui

Background: It has been shown that expression of the potent angiogenic factor, vascular endothelial growth factor (VEGF), and its receptors, flt-1 (VEGFR-1) and KDR/Flk-1 (VEGFR-2), increased during the development of liver fibrosis.

Aims: To elucidate the in vivo role of interaction between VEGF and its receptors in liver fibrogenesis.

Methods: A model of CCl₄-induced hepatic fibrosis was used to assess the role of VEGFR-1 and VEGFR-2 by means of specific neutralising monoclonal antibodies (R-1mAb and R-2mAb, respectively). R-1mAb and R-2mAb were administered after two weeks of treatment with CCl₄, and indices of fibrosis were assessed at eight weeks.

Results: Hepatic VEGF mRNA expression significantly increased during the development of liver fibrosis. Both R-1mAb and R-2mAb treatments significantly attenuated the development of fibrosis associated with suppression of neovascularisation in the liver. Hepatic hydroxyproline and serum fibrosis markers were also suppressed. Furthermore, the number of α-smooth muscle actin positive cells and α(I)-procollagen mRNA expression were significantly suppressed by R-1mAb and R-2mAb treatment. The inhibitory effect of R-2mAb was more potent than that of R-1mAb, and combination treatment with both mAbs almost completely attenuated fibrosis development. Our in vitro study showed that VEGF treatment significantly stimulated proliferation of both activated hepatic stellate cells (HSC) and sinusoidal endothelial cells (SEC). VEGF also significantly increased α(I)-procollagen mRNA expression in activated HSC.

Conclusions: These results suggest that the interaction of VEGF and its receptor, which reflected the combined effects of both on HSC and SEC, was a prerequisite for liver fibrosis development.

Abbreviations: α-SMA, α-smooth muscle actin; ALT, aminotransferase; aspartate, A-M; Asan-Mallory; ECM, extracellular matrix; EC, endothelial cells; HSC, hepatic stellate cells; IgG, immunoglobulin G; mAb, neutralising monoclonal antibody; PCR, polymerase chain reaction; P, procollagen III-N-peptide; R-1mAb, VEGFR-1 monoclonal antibody; R-2mAb, VEGFR-2 monoclonal antibody; SEC, hepatic sinusoidal endothelial cells; VEG, vascular endothelial growth factor; VEGFR-1, fms-like tyrosine kinase (flt-1); VEGFR-2, kinase-insert domain-containing receptor/fetal liver kinase-1 (KDR/Flk-1); vWF, von Willebrand factor.
Two tyrosine kinases, fms-like tyrosine kinase (Flt-1: VEGFR-1) and the kinase insert domain-containing receptor/murine homologue, fetal liver kinase-1 (KDR/Fk-1: VEGFR-2), both of which are type III tyrosine kinase receptors, have been identified as the main VEGF receptors. By binding with high affinity to these two receptors, VEGF can stimulate EC proliferation, migration, and differentiation, and can induce angiogenesis in vitro and in vivo.\textsuperscript{11,16} It has been shown that these two receptors serve different biological roles in many pathological events.\textsuperscript{12–20} It has been reported that VEGFR-2 plays a more important role both in vitro and in vivo.\textsuperscript{11,16} However, recent studies have revealed that VEGFR-1 also plays certain roles in pathological angiogenesis, such as tumour growth.\textsuperscript{14,15} It has been shown that expression of VEGFR-1 and VEGFR-2 was induced during activation of HSC in vitro, although the upregulation patterns were different under different culture conditions, such as hypoxia and CCl\textsubscript{4} treatment.\textsuperscript{12–14} In experimental liver fibrogenesis, it has been reported that VEGFR-1 expression increased in the liver, and VEGFR-2 was constitutively highly expressed although its expression level was not significantly altered.\textsuperscript{11,16} The in vivo role of the interaction between VEGF and its receptor in liver fibrosis development has not yet been elucidated.

In the present study, using the specific neutralising monoclonal antibodies of VEGFR-1 and VEGFR-2, we examined the biological role of VEGF and its receptors in the progression of liver fibrosis.

METHODS

Animals

Male BALB/c mice, aged six weeks, were purchased from Japan SLC Inc. (Hamamatsu, Shizuoka, Japan). They were housed in stainless steel mesh cages under controlled conditions (temperature 23±3°C and relative humidity 50±20%), with 10–15 air changes per hour and light illumination for 12 hours a day. The animals were allowed access to food and tap water ad libitum throughout the acclimatisation and experimental periods.

Compounds and animal treatment

Anti-VEGFR-1 and VEGFR-2 specific neutralising antibodies (R-1mAb and R-2mAb, respectively) were generated as described previously.\textsuperscript{11,15–16} Briefly, these antibodies were produced under large scale culture conditions in serum free media. The monoclonal antibodies (mAbs) were purified from conditioned media by affinity chromatography on a Gammabind-G-Sepharose column (Pharmacia Biotech, Piscataway, New Jersey, USA). The purity of the respective receptors was >99%, as determined by sodium dodecyl sulphate-polyacrylamide gel electrophoresis, and were verified to be free of endotoxin (<1 EU/ml) using a limulus amoebocyte lysate endotoxin detection kit (Pyrogen Tplus, Bio-Whittaker, Walkersville, Maryland, USA). It has been shown that R-2mAb exerts a VEGFR-2 inhibitory effect in a dose dependent manner such that the maximal effect is achieved at a dose of 800 µg/mouse administered twice a week.\textsuperscript{16,17} We thus employed this dose in the current study.

Mice were divided into four groups (n=10 in each group). All experimental groups received CCl\textsubscript{4}, (2 ml/kg/body weight dissolved in 150 µl of corn oil) twice a week to develop liver fibrosis. After two weeks of treatment with CCl\textsubscript{4}, R-1mAb and R-2mAb (800 µg/mouse) were administered intraperitoneally to group 2 (G2) and group 3 (G3) twice a week on days different from those on which CCl\textsubscript{4} was injected, respectively. In group 4 (G4), both R-1mAb and R-2mAb were administered simultaneously. Animals in group 1 (G1) received the same amount of control immunoglobulin G (IgG) as described previously.\textsuperscript{18} Mice which received only corn oil were examined as a negative control group. After eight weeks of treatment with CCl\textsubscript{4}, all mice were killed under anaesthesia.

![Figure 1 Vascular endothelial growth factor (VEGF) mRNA expression in the CCl\textsubscript{4} treated liver. VEGF mRNA expression was examined by real-time polymerase chain reaction as described in the methods section. Hepatic VEGF expression increased during liver fibrosis development. Neither R-1 mAb nor R-2 mAb treatment altered VEGF gene expression during development of fibrosis. Control, immunoglobulin G treated mice (800 µg/mouse) (G1); R-1, R-1 mAb and R-2 mAb treated mice (800 µg/mouse) (G2 and G3, respectively); R1+R2, R-1 mAb and R-2 mAb combination treated group (G4); Oil, corn oil injected negative control mice. Data are means (SD; n=5).](http://gut.bmj.com/)

All animal procedures were performed according to approved protocols and in accordance with the standard recommendations for the proper care and use of laboratory animals.

Histological and immunohistochemical examinations

In all experimental groups, 5 µm thick sections of formalin fixed and paraffin embedded livers were processed routinely for Azan-Mallory (A-M) staining for determination of liver fibrosis development. Immunohistochemical staining of α smooth muscle actin (α-SMA) was performed as previously described using paraffin embedded sections with a primary anti-α-SMA antibody (Dako, Kyoto, Japan).\textsuperscript{18,25} Semiquantitative analyses of fibrosis development and the immunopositive cell area were carried out with the Fuji BAS 2000 image analysis system (Fuji, Tokyo, Japan) in six ocular fields (40x magnification) per specimen from five mice. We did not count α-SMA positive vessels in the portal area which were assumed to be hepatic arteries. We only included α-SMA positive cells in the sinusoidal lining for image analysis.\textsuperscript{17,20}

Hepatic hydroxyproline content and serum markers

Hepatic hydroxyproline content was determined as previously described with 200 mg of frozen samples.\textsuperscript{18} The hydroxyproline content was expressed as µg/g wet liver. Alanine aminotransferase (ALT) and total bilirubin were assessed using routine laboratory methods. Serum hyaluronic acid and procollagen III-N-peptide (P-III-P) were also measured as described previously.\textsuperscript{18}

Immunoprecipitation

To determine whether R-1mAb and R-2mAb at a dose of 800 µg/mouse suppressed autophosphorylation of the respective receptors in the liver, immunoprecipitation was performed as previously described.\textsuperscript{18} Fifteen minites after R-1mAb and R-2mAb were injected intraperitoneally, the liver was resected from three mice in each group and snap frozen immediately. The liver pool lysate solution was concentrated and used for immunoprecipitation. To conduct immunoprecipitation, liver lysates were immunoprecipitated with antiphosphotyrosine before conducting sodium dodecyl sulphate-polyacrylamide gel electrophoresis. Antitrypsin (4G10) was purchased from Upstate Biotechnology (New York, USA) and anti-VEGFR-2 (C-1158) and VEGFR-1 (C-17) were obtained from Santa Cruz (California, USA). Before western blotting, we stained each membrane with Ponceau solution (Sigma, Michigan, USA) to confirm that the same amounts of protein were immunoprecipitated (data not shown). The blots were developed using an amplified alkaline phosphatase immuno blot assay kit (Bio-Rad, California, USA).
RNA expression of VEGF, CD-31, and α1-(I)-procollagen by real time polymerase chain reaction

The VEGF, CD-31, which is used widely as a marker for neovascularisation, and α1-(I)-procollagen mRNA expression were evaluated by real time polymerase chain reaction (PCR), as described previously. mRNA was extracted from the whole liver of the animals in each experimental group (n=5). For cDNA synthesis, Taqman reverse transcription reagents were used as described in the manufacturer’s manual of the ABI Prism 7700 Sequence Detection System (PE Applied Biosystems, Foster City, California, USA), which was used for real-time PCR amplification following the Taqman Universal PCR Master Mix Protocol (PE Applied Biosystems). Relative quantitation of gene expression was performed as described in the manual, using glyceraldehyde-3-phosphate dehydrogenase as an internal control. The threshold cycle and standard curve method was used for calculating the relative amount of the target RNA, as described for PE. The following temperatures were employed: hold at 50°C for two minutes, hold at 60°C for 30 minutes, hold at 94°C for five minutes, cycle 45 repeats at 94°C for one minute, at 55°C for one minute, and at 72°C for one minute. To prevent genomic DNA contamination, all RNA samples were subjected to DNase I digestion and checked by 40 cycles of PCR to confirm the absence of amplified DNA.

Isolation and culture of HSC and SEC

R-1mAb and R-2mAb only react with mice receptors and not with those of other species, such as the rat. Although we attempted several times to isolate pure HSC from the liver of mice, contamination with other types of non-parenchymal cells, such as EC, could not be ruled out. Furthermore, the yield of purified HSC from mice was too low to perform several experiments, as described previously. We thus employed HSC from the liver of the rat, and examined the effect of VEGF treatment on VEGF-receptor interaction in activated HSC.

Figure 2 Microphotographs of liver sections from CCl4 treated mice. (A) Control immunogloblin G treated group after CCl4 treatment (800 µg/mouse) [G1]. (B, C) R-1mAb and R-2mAb treated (800 µg/mouse) groups [G2 and G3, respectively]. (D) R-1mAb and R-2mAb combination treated group [G4]. The livers in G1 show extensive fibrosis development. In G2 and G3, liver fibrosis development was significantly attenuated, and the inhibitory impact was more potent with R-2mAb treatment than with R-1mAb treatment. Fibrosis development was almost completely abolished in the livers of G4 (A-M staining, 40×).

Figure 3 Effects of R-1mAb and R-2mAb on fibrosis area (A) and hepatic hydroxyproline content (B) in the CCl4 treated liver. (A) Fibrosis area was evaluated by an image analyser, as described in the methods section. R-1mAb and R-2mAb significantly suppressed liver fibrosis development compared with the control group (p<0.01), and the inhibitory impact was more potent with R-2mAb treatment than that with R-1mAb treatment (p<0.01). The combination treatment with both mAbs revealed further inhibition compared with that of R-2mAb alone (p<0.05). (B) The inhibitory effects of R-1mAb and R-2mAb on hepatic hydroxyproline content exerted behaviours similar to those on fibrosis area. Control, immunogloblin G treated mice (800 µg/mouse) [G1], R1, R2, R-1mAb and R-2mAb treated mice [800 µg/mouse] [G2 and G3, respectively], R1+R2, R-1mAb and R-2mAb combination treated group [G4], Oil, corn oil injected negative control mice. Data are means (SD) (n=5), *p<0.05, **p<0.01 between the indicated groups.
Liver HSC were isolated from the liver of F344 rats, as described previously, with a minor modification. Briefly, the liver was perfused with Krebs-Ringer solution followed by 0.1% pronase E and 0.032% collagenase (Nakarai, Kyoto, Japan) solution at 37°C. The digested liver was cut, minced, and incubated in Krebs-Ringer solution containing 0.08% pronase E, 0.04% collagenase, and 20 µl/mM DNase for 30 minutes at 37°C (pH 7.3). After passage through a nylon mesh, cells were centrifuged at 450 g for eight minutes. The HSC enriched fraction was obtained by centrifugation in 8.2% Nycodenz (Nycomed Pharma AS, Oslo, Norway) solution at 1400 g for 20 minutes. HSC in the upper white layer were washed by centrifugation at 450 g for eight minutes and suspended in DMEM medium containing 10% fetal calf serum, Nycodenz (Nycomed Pharma AS, Oslo, Norway) solution at 37°C. The digested liver was cut, minced, and incubated in Krebs-Ringer solution containing 0.08% pronase E, 0.04% collagenase, and 20 µl/mM DNase for 30 minutes at 37°C (pH 7.3). After passage through a nylon mesh, cells were centrifuged at 450 g for eight minutes. The HSC enriched fraction was obtained by centrifugation in 8.2% Nycodenz (Nycomed Pharma AS, Oslo, Norway) solution at 1400 g for 20 minutes. HSC in the upper white layer were washed by centrifugation at 450 g for eight minutes and suspended in DMEM medium containing 10% fetal calf serum, Nycodenz (Nycomed Pharma AS, Oslo, Norway) solution at 37°C. The digested liver was cut, minced, and incubated in Krebs-Ringer solution containing 0.08% pronase E, 0.04% collagenase, and 20 µl/mM DNase for 30 minutes at 37°C (pH 7.3). After passage through a nylon mesh, cells were centrifuged at 450 g for eight minutes. The HSC enriched fraction was obtained by centrifugation in 8.2% Nycodenz (Nycomed Pharma AS, Oslo, Norway) solution at 1400 g for 20 minutes. HSC in the upper white layer were washed by centrifugation at 450 g for eight minutes and suspended in DMEM medium containing 10% fetal calf serum, Nycodenz (Nycomed Pharma AS, Oslo, Norway) solution at 37°C. The digested liver was cut, minced, and incubated in Krebs-Ringer solution containing 0.08% pronase E, 0.04% collagenase, and 20 µl/mM DNase for 30 minutes at 37°C (pH 7.3). After passage through a nylon mesh, cells were centrifuged at 450 g for eight minutes. The HSC enriched fraction was obtained by centrifugation in 8.2% Nycodenz (Nycomed Pharma AS, Oslo, Norway) solution at 1400 g for 20 minutes. HSC in the upper white layer were washed by centrifugation at 450 g for eight minutes and suspended in DMEM medium containing 10% fetal calf serum, Nycodenz (Nycomed Pharma AS, Oslo, Norway) solution at 37°C. The digested liver was cut, minced, and incubated in Krebs-Ringer solution containing 0.08% pronase E, 0.04% collagenase, and 20 µl/mM DNase for 30 minutes at 37°C (pH 7.3). After passage through a nylon mesh, cells were centrifuged at 450 g for eight minutes. The HSC enriched fraction was obtained by centrifugation in 8.2% Nycodenz (Nycomed Pharma AS, Oslo, Norway) solution at 1400 g for 20 minutes. HSC in the upper white layer were washed by centrifugation at 450 g for eight minutes and suspended in DMEM medium containing 10% fetal calf serum, Nycodenz (Nycomed Pharma AS, Oslo, Norway) solution at 37°C. The digested liver was cut, minced, and incubated in Krebs-Ringer solution containing 0.08% pronase E, 0.04% collagenase, and 20 µl/mM DNase for 30 minutes at 37°C (pH 7.3). After passage through a nylon mesh, cells were centrifuged at 450 g for eight minutes. The HSC enriched fraction was obtained by centrifugation in 8.2% Nycodenz (Nycomed Pharma AS, Oslo, Norway) solution at 1400 g for 20 minutes. HSC in the upper white layer were washed by centrifugation at 450 g for eight minutes and suspended in DMEM medium containing 10% fetal calf serum, Nycodenz (Nyomed...
effects of R-1mAb and R-2mAb on the acute liver injury and early liver fibrogenesis step. It has been shown that Masson’s trichrome positive connective tissue accumulation could be observed on day 7 after CCl4 treatment.

Two or seven days after CCl4 treatment, R-1mAb and R-2mAb did not alter ALT levels in the liver (data not shown). This indicated that the inhibitory effect of mAbs was not a secondary response to a cytoprotective effect against CCl4. Body and liver weights when the mice were killed were not significantly different between the control, R-1mAb treated, and R-2mAb treated groups (data not shown).

Neovascularisation

To examine whether the inhibitory effects of R-1mAb and R-2mAb were associated with suppression of neovascularisation in the liver, we evaluated the angiogenic response during liver fibrosis development. We performed a preliminary immunohistochemical analysis of the von Willebrand factor (vWF) related antigen on sections from all experimental groups, and found that R-1mAb/R-2mAb treatment significantly suppressed vWF positive vessels. However, it was hard to accurately evaluate vWF positive cells because of difficulties in identifying the little slit vessels in the R-1mAb and R-2mAb combination treated group (data not shown). It has been reported that CD34 is a more sensitive marker than vWF related antigen. CD31 was also shown to be a sensitive marker in ECs. Among these markers, it has been reported that CD34 expression may be decreased by VEGF. We thus used CD31 expression in the current study.

We performed real time PCR analysis of CD31 gene expression to evaluate neovascularisation in the liver. Figure 4 demonstrates that CD31 gene expression was significantly increased in association with liver fibrosis development. Similar to fibrosis area, both R-1mAb and R-2mAb significantly suppressed CD31 gene expression compared with the control group (p<0.01). The inhibitory impact was more potent with R-2mAb treatment than that with R-1mAb treatment (p<0.01), and the combination treatment of both mAbs almost abolished neovascularisation in the liver. Noteworthy was the finding that suppression of angiogenesis by treatment with R-1mAb and R-2mAb was of a similar magnitude to that of inhibition of fibrosis areas.

Figure 5 Immunohistochemical analysis of α smooth muscle actin (α-SMA). Immunopositive cells of α-SMA were significantly reduced in the livers of R-1mAb (B), R-2mAb (C), and the combination of R-1mAb and R-2mAb treated groups (D) compared with the control group (A) (G1) (magnification ×40).

Figure 6 Densitometric analysis of α smooth muscle actin (α-SMA) positive cells (A) and α1(I) procollagen mRNA expression (B) in the CCl4 treated liver. α-SMA positive activated hepatic stellate cells and α1(I) procollagen mRNA were significantly reduced by R-1mAb and R-2mAb treatment. The inhibitory effect of R-2mAb was more potent than that of R-1mAb. The inhibitory effects of R-1mAb and R-2mAb on α-SMA and α1(I)- procollagen expression exerted almost parallel reductions. Control, immunoglobulin G treated mice (800 µg/mouse) (G1); R1, R2, R-1mAb and R-2mAb treated mice (800 µg/mouse) [G2 and G3, respectively]; R1+R2, R-1mAb and R-2mAb combination treated group (G4); Oil, corn oil injected negative control mice. Data are means (SD) (n=5). *p<0.05, **p<0.01 between the indicated groups.
VEGFR-1 and VEGFR-2 receptor activation in situ

To determine whether R-1mAb and R-2mAb at the dose used in the current study (800 µg/mouse) inhibited autophosphorylation in the liver, we investigated tyrosine phosphorylated VEGFR-1 and VEGFR-2 in the liver after intraperitoneal injection of R-1mAb and R-2mAb. R-1mAb and R-2mAb significantly inhibited tyrosine phosphorylation of the respective receptors, and the combination treatment of R-1mAb and R-2mAb almost completely abolished phosphorylation of both receptors in the liver.

Neither activation of VEGFR-1 nor that of VEGFR-2 was altered by administration of R-2mAb and R-1mAb, respectively (fig 7).

Effect of VEGF on cultured activated HSC and SEC

It has been reported that HSC plated on collagen I are activated progressively whereas those on a basement membrane substrate resembling the normal subendothelial matrix of the liver (EHS matrix) remain quiescent. We examined the effect of VEGF on HSC proliferation under different culture conditions. Figure 7 shows that both 10 and 100 ng/ml VEGF treatment did not increase in vitro proliferation on an EHS matrix whereas it was stimulated significantly on a collagen I coated dish (p<0.05), indicating that VEGF stimulated activated HSC proliferation but not quiescent HSC. We also examined whether VEGF increased synthesis of the extracellular matrix (ECM) component in activated HSC. As shown in fig 8B, VEGF treatment at a dose of 10 ng/ml significantly upregulated α1(1)-procollagen mRNA synthesis in activated HSC.

We next examined the effect of VEGF on SEC proliferation. As it has been shown that VEGF is a survival factor for SEC, we chronologically examined the proliferation assay of SEC in the presence of VEGF (10 ng/ml). Figure 8C reveals that proliferation of SEC was significantly increased on stimulation with VEGF over time. Without VEGF, these cells rapidly atrophied and died in a few days. We also examined whether VEGF induced production of factors by SEC that may have an impact on HSC biology, such as platelet derived growth factor and transforming growth factor β. We found that neither factor was increased by treatment with VEGF in SEC (data not shown). In addition to the MTT assay, we performed the [H] incorporation experiment for in vitro proliferation of both HSC and SEC. Our results were similar to those of previously reported¹⁵ MTT and [H] incorporation assays (data not shown).

Effects of R-1mAb and R-2mAb on HSC activation

It has been reported that not only SEC, but also activated HSC, express both VEGFR-1 and VEGFR-2. Immunochemical analysis showed that α-SMA positive cells were drastically reduced by treatment with R-1mAb and R-2mAb (fig 5A–5D). Computer assisted semiquantitative analysis showed that α-SMA positive cells in the R-1mAb and R-2mAb treated groups were significantly reduced compared with the control group (p<0.01) (fig 6A). The inhibitory effects of R-2mAb on both α-SMA positive cells and α-SMA(1)-procollagen mRNA expression were significantly stronger than those of R-1mAb (p<0.01). The inhibitory effects of R-1mAb and R-2mAb on α-SMA, α-SMA(1)-procollagen mRNA expression, and fibrosis area were almost identical, suggesting that suppression of HSC activation also contributed to the antifibrotic effect of these mAbs.

VEGF and α-SMA positive cells were almost identical, suggesting that suppression of HSC activation also contributed to the antifibrotic effect of VEGF.

Figure 7 Effects of R-1mAb and R-2mAb on the activation of vascular endothelial growth factor (VEGF) receptors VEGFR-1 (fms-like tyrosine kinase [Flk-1]) and VEGFR-2 (kinase insert domain-containing receptor/tyrosine kinase-1 [Flt-1]) and VEGFR-2 in the liver after intraperitoneal injection of R-1mAb and R-2mAb, the liver was resected from three mice and pooled. The liver lysate was concentrated and used for immunoprecipitation, as described in the methods section. R-1mAb and R-2mAb significantly inhibited tyrosine phosphorylation of the respective receptors. Neither activation of VEGFR-1 nor that of VEGFR-2 was altered by administration of R-2mAb and R-1mAb, respectively. The activation level of VEGFR-1 was lower than that of VEGFR-2. Lane 1, immunoglobulin G treated control group (G1); lane 2, R-1mAb treated group (G2); lane 3, R-2mAb treated group (G3); lane 4, R-1mAb and R-2mAb combination treated group (G4); and lane 5, corn oil treated negative control group.

Figure 8 Effect of vascular endothelial growth factor (VEGF) on proliferation and α1(1)-procollagen mRNA expression of activated hepatic stellate cells (HSC) and hepatic sinusoidal endothelial cells (SEC) in vitro. Cell proliferation and mRNA expression were measured by the MTT assay and real time polymerase chain reaction, as described in the methods section, respectively. (A) At doses of 10 and 100 ng/ml, VEGF treatment did not increase the in vitro proliferation of HSC on a collagen I (Col-I). *p<0.05 compared with the control group. Control, untreated control group; VEGF, VEGF treated groups at doses of 10 and 100 ng/ml. (B) At a dose of 10 ng/ml, VEGF significantly increased α1(1)-procollagen mRNA synthesis in activated HSC. **p<0.01 compared with the VEGF untreated group. (C) Proliferation of SEC was significantly increased over time on stimulation with VEGF (10 ng/ml). OD, optical density. *p<0.05, **p<0.01 compared with day 1. Data are means (SD) (n=3).
DISCUSSION

Angiogenesis and fibrosis are key components in development, growth, wound healing, and regeneration. Recent studies have revealed that these processes commonly occur together in many disease states where neovascularisation is believed to initiate the pathological cascade. Among the identified angiogenic factors to date, VEGF is one of the most potent and central factors in many physiological and pathological processes. In liver fibrosis, it has been shown that VEGF expression increased in both human chronic liver diseases and experimental fibrogenesis. It has also been reported that VEGF expression correlates with chronic liver disease associated angiogenesis and sinusoidal capillarisation. We also observed that VEGF gene expression significantly increased during fibrosis development associated with neovascularisation in the liver, and that suppression of VEGF-receptor interaction significantly attenuated progression of liver fibrosis and angiogenesis.

The biological activities of VEGF are mediated mainly via two type III tyrosine kinase receptors—namely, VEGFR-1 and VEGFR-2—which serve different roles in angiogenesis and signal transduction pathways. It has been reported that VEGFR-2 plays a more important role both in vitro and in vivo in several biological events. Overexpression of VEGF-2 in porcine EC caused actin reorganisation, chemotaxis, and mitogenesis in response to VEGF, although VEGFR-1 expression in the same cells had a minimal effect in vitro. However, recent studies have revealed that VEGFR-1 is also involved in pathological angiogenesis, such as tumour growth. In the present study, we found that inhibition of either VEGFR-1 or VEGFR-2 significantly attenuated liver fibrogenesis accompanied by angiogenesis suppression, and that treatment with R-2mAb was more potent than that with R-1mAb. The combination treatment with both mAbs almost completely attenuated liver fibrogenesis. These results indicate that VEGF-receptor interaction is a major regulator of the process of liver fibrosis. Both VEGFR-1 and VEGFR-2 were involved in liver fibrogenesis, and signalling through VEGFR-2 was a predominant pathway compared with that via VEGFR-1.

It is now recognised that activated HSC play an important role in liver fibrosis development. In addition to EC, recent studies have shown that expression of VEGF and its receptor occurs in activated HSC. This indicates that the cellular targets of VEGF are not confined to EC, and that VEGF responses reflect the combined effects on both EC and HSC. Recently, it has been shown that hypoxia induced VEGF expression was associated with angiogenesis and liver fibrogenesis. The authors showed that hepatic VEGFR-1 expression increased in liver fibrogenesis, which probably originated from activated HSC. The in vitro study showed that VEGFR-1 was selectively increased in activated HSC under hypoxic conditions whereas expression of VEGFR-2 was not upregulated. However, it should be noted that VEGFR-2 was constitutively expressed in activated HSC, and that the expression level of VEGFR-2 was much higher than that of VEGFR-1. We found that activated α-SMA positive HSC and α-VEGF(1)-procollagen mRNA were significantly suppressed by R-1mAb and R-2mAb. It has been reported that α-SMA expression in activated HSC may be downregulated by VEGF. The authors also claimed that VEGF did not affect proliferation of activated HSC in vitro. In contrast, we and others have shown different results under different culture conditions. They suggested that VEGF exerts a different biological effect on activated HSC under different culture conditions. After liver injury, HSC proliferate and become activated to the myofibroblastic phenotype, which is characterised by an increase in expression of α-SMA. As is now widely recognised that α-SMA is a useful and reliable marker for in vivo fibrogenesis, we also employed this marker in the current study.

We also found that VEGF stimulated proliferation of activated HSC in vitro, indicating that VEGF-receptor interaction in HSC also plays an important role in liver fibrogenesis. We found that HSC did not respond to VEGF when they were cultured on Matrigel. Matrigel may sequester VEGF as it can bind with the proteoglycans of Matrigel. However, we found similar effects with low and high exogenous VEGF treatment (10 ng/ml and 100 ng/ml, respectively). With high doses of VEGF, we assume that VEGF can act on HSC even if Matrigel may sequester some part of VEGF. A similar effect of VEGF on activated HSC in Matrigel has been reported. It would be important to elucidate the binding sites of R-1mAb and R-2mAb during liver fibrogenesis. We attempted to localise these binding sites of mAbs by immunohistochemical double staining but we failed to obtain good results. The background was very intense, and interpretation was very difficult (data not shown). Furthermore, the specific role of each receptor in activated HSC remains obscure at this time as we could not obtain specific R-1mAb and R-2mAb for the rat. When mAbs against rat VEGFR-1 and VEGFR-2 became available, further studies may elucidate the role of each receptor in liver fibrogenesis.

VEGF was originally identified as a vascular permeability factor that increased microvessel permeability approximately 50 000 times more than histamine. It induces extravasation of plasma proteins, leading to an increase in the ECM. It has also been reported that VEGF increased mRNA levels of connective tissue growth factor, which has known actions on ECM production. In the current study, we found that VEGF significantly increased α1(I)-procollagen mRNA in activated HSC, indicating that VEGF stimulates liver fibrogenesis through both ECM production and proliferation in activated HSC. Nevertheless, it is well known that HSC are the primary ECM producing cell type but SEC also respond rapidly to injury by synthesising an isoform of the cellular fibronectin that stimulates HSC activation. It may also stimulate fibrosis development through these biological activities.

In summary, hepatic VEGF mRNA expression was significantly increased during the development of fibrosis, and both R-1mAb and R-2mAb treatment significantly attenuated the fibrogenesis associated with suppression of neovascularisation in the liver. The inhibitory effect of R-2mAb was more potent than that of R-1mAb, and the combination treatment with R-1mAb and R-2mAb almost completely attenuated liver fibrosis development. α-SMA positive activated HSC and α-VEGF(1)-procollagen mRNA were significantly suppressed by R-1mAb and R-2mAb, and VEGF stimulated proliferation of activated HSC in vitro. These results suggest that interaction between VEGF and its receptors, which reflected the combined effects of both on HSC and SEC, was a prerequisite for liver fibrosis development.

ACKNOWLEDGEMENTS

The work was supported in part by a Grant-in-Aid for Scientific Research (C-14570498) from the Japanese Ministry of Education, Science, Sports, and Culture.

Authors' affiliations


REFERENCES


A The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology 2001; 33: 841-7.

A The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology 2001; 33: 841-7.

A The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology 2001; 33: 841-7.

A The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology 2001; 33: 841-7.